09
Dec
Isolating Promoter Sequences for Analysis

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, and Synpromics Limited, a leading synthetic promoter development company backed by Calculus Capital, today announced they have entered into a broad, multi-target collaboration agreement.

14
Aug
Synpromics Chemical Stocks

Synpromics announces that it has completed a financing round including £2.1m of new funding from Calculus Capital (“Calculus”). The funds will be used for business expansion and further development of Synpromics’ proprietary synthetic promoter technology.

04
Mar
Characterisation of Synthetic Promoter Activity

Synpromics Limited, a leading synthetic biology company, is pleased to announce that it has formed a collaboration with uniQure N.V., a world leader and pioneer in human gene therapy, to develop synthetic promoters with specific application in the delivery of gene medicines to liver.

20
Aug
Creating Bacterial Synthetic Promoters

Synpromics Limited, a privately held, Scottish-based synthetic biology company today announced that it has successfully generated several highly effective synthetic promoters for use in plants.

27
Mar
Eucaryotic Synthetic Promoter Library Screening

Collaborating with a leading multinational company is an exceptional achievement for this young biotechnology company, based at Edinburgh BioQuarter.

Pages